Tuesday - May 6, 2025
KALAMAZOO, Michigan, USA, July 6, 2023 /PRNewswire/ -- Stryker (NYSE:SYK) announced the launch of its Ortho Q Guidance system, the only fully autonomous system in the industry, easily controlled by the surgeon from the sterile field. The system combines new optical tracking options via a redesigned, state-of-the-art camera with sophisticated algorithms of the newly launched Ortho Guidance software to deliver additional surgical planning and guidance capabilities When used with Ortho Q, the Ortho Guidance software for Express Knee, Precision Knee and Versatile Hip serves as a planning and intraoperative guidance system that enhances procedural speed and efficiency through a smart, streamlined workflow.
"Ortho Q was designed specifically for our orthopaedic customers and is the culmination of a multiyear collaboration between teams in India, Germany and the United States. This platform builds a foundation for the future of orthopaedic surgical capability," said Bill Scott, vice president and general manager of Stryker's Orthopaedic Instruments business.
Ortho Q Guidance system features include:
For more information, please visit Stryker's Ortho Q Guidance product page at https://www.stryker.com/us/en/orthopaedic-instruments/c/Ortho-Q-Guidance.html
About Stryker
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Media contact
Hillary Eley
Sr. Manager, Strategic Communications
Instruments
hillary.eley@stryker.com
Last Trade: | US$381.36 |
Daily Change: | 3.14 0.83 |
Daily Volume: | 1,600,013 |
Market Cap: | US$145.380B |
May 01, 2025 March 04, 2025 March 03, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load